Oxidized haemoglobin-driven endothelial dysfunction and immune cell activation: Novel therapeutic targets for atherosclerosis

Current Medicinal Chemistry

Volumn 20, Issue 37, 2013, Pages 4806-4814

  Buttari, Brigitta ^a   Profumo, Elisabetta ^a   Businaro, Rita ^b   Saso, Luciano ^b   Capoano, Raffaele ^b   Salvati, Bruno ^b   Riganò, Rachele ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Adaptive immunity; Atherosclerosis; CD163; Endothelial cells; Haptoglobin; Innate immunity; Oxidized haemoglobin; Therapeutic perspectives

Indexed keywords

AUTOANTIGEN; CD163 ANTIGEN; HAPTOGLOBIN; OXYHEMOGLOBIN;

ADAPTIVE IMMUNITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNITY; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INNATE IMMUNITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN MODIFICATION;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ATHEROSCLEROSIS; DENDRITIC CELLS; ENDOTHELIUM, VASCULAR; HEMOGLOBINS; HUMANS; IMMUNITY, INNATE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTORS, CELL SURFACE;

EID: 84889260977     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990162     Document Type: Article

References (85)

1. Libby, P.; Ridker, P.M.; Hansson, G.K. Progress and challenges in translating the biology of atherosclerosis. Nature, 2011, 19(473), 317-325.
2. Hansson, G.K.; Hermansson, A. The immune system in atherosclerosis. Nat. Immunol., 2011, 12(3), 204-212.
3. Moore, K.J.; Tabas, I. Macrophages in the pathogenesis of atherosclerosis. Cell, 2011, 145(3), 341-355.
4. Boyle, J.J.; Harrington, H.A.; Piper, E.; Elderfield, K.; Stark, J.; Landis, R.C.; Haskard, D.O. Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype. Am. J. Pathol., 2009, 174(3), 1097-1108.
5. Ueno, H.; Klechevsky, E.; Morita, R.; Aspord, C.; Cao, T.; Matsui, T.; Di Pucchio, T.; Connolly, J.; Fay, J.W., Pascual, V.; Palucka, A.K.; Banchereau, J. Dendritic cell subsets in health and disease. Immunol. Rev., 2007, 219, 118-142. (Pubitemid 47393528)
6. Mallat, Z.; Ait-Oufella, H.; Tedgui, A. Regulatory T-cell immunity in atherosclerosis. Trends Cardiovasc. Med., 2007, 17(4), 113-118. (Pubitemid 46670020)
7. Osterud, B.; Bjorklid, E. Role of monocytes in atherogenesis. Physiol. Rev., 2003, 83(4), 1069-1112. (Pubitemid 37222268)
8. Yilmaz, A.; Lochno, M.; Traeg, F.; Cicha, I.; Reiss, C.; Stumpf, C.; Raaz, D.; Anger, T.; Amann, K.; Probst, T.; Ludwig, J.; Daniel, W.G.; Garlichs, C.D. Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis, 2004, 176(1), 101-110. (Pubitemid 39078651)
9. Ranjit, S.; Dazhu, L. Potential role of dendritic cells for progression of atherosclerotic lesions. Postgrad. Med. J., 2006, 82, 573-575. (Pubitemid 44476212)
10. Dansky, H.M.; Charlton, S.A.; Harper, M.M.; Smith, J.D. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. U S A, 1997, 94(9), 4642-4646. (Pubitemid 27194296)
11. Daugherty, A.; Puré, E.; Delfel-Butteiger, D.; Chen, S.; Leferovich, J.; Roselaar, S.E.; Rader, D.J. The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice. J. Clin. Invest., 1997, 100(6), 1575-1580. (Pubitemid 27425785)
12. Reardon, C.A.; Blachowicz, L.; White, T.; Cabana, V.; Wang, Y.; Lukens, J.; Bluestone, J.; Getz, G.S. Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein Edeficient mice. Arterioscler. Thromb. Vasc. Biol., 2001, 21(6), 1011-1016. (Pubitemid 34168661)
13. Song, L.; Leung, C.; Schindler, C. Lymphocytes are important in early atherosclerosis. J. Clin. Invest., 2001, 108(2), 251-259. (Pubitemid 32656249)
14. Tedgui, A.; Mallat, Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev., 2006, 86(2), 515-581.
15. Ait-Oufella, H.; Taleb, S.; Mallat, Z.; Tedgui, A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2011, 31(5), 969-979.
16. George, J.; Schwartzenberg, S.; Medvedovsky, D.; Jonas, M; Charach, G.; Afek, A.; Shamiss, A. Regulatory T cells and IL-10 levels are reduced in patients with vulnerable coronary plaques. Atherosclerosis, 2012, 222(2), 519-523.
17. Profumo, E.; Buttari, B.; Tosti, M.E.; Alessandri, C.; Valesini, G.; Marcuccio, L.; Tesori, C.; Capoano, R.; Salvati, B.; Riganò, R. Identification of IP-10 and IL-5 as proteins differentially expressed in human complicated and uncomplicated carotid atherosclerotic plaques. Int. J. Immunopathol. Pharmacol., 2010, 23(3), 775-782.
18. Miossec, P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect., 2009, 11(5), 625-630.
19. Taleb, S.; Tedgui, A.; Mallat, Z. Interleukin-17: friend or foe in atherosclerosis? Curr. Opin. Lipidol., 2010, 21(5), 404-408.
20. George, J. Mechanisms of disease: the evolving role of regulatory T cells in atherosclerosis. Nat. Clin. Pract. Cardiovasc. Med., 2008, 5(9), 531-540.
21. Tabas, I.; Williams, K.J.; Borén, J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation, 2007, 116(16), 1832-1844. (Pubitemid 350287108)
22. Di Minno, M.N.; Iervolino, S.; Peluso, R.; Scarpa, R.; Di Minno, G. CaRRDs study group. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler. Thromb. Vasc. Biol., 2011, 31(3), 705-712.
23. Klingenberg, R.; Hansson, G.K. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur. Heart J., 2009, 30(23), 2838-2844.
24. Profumo, E.; Buttari, B.; Tosti, M.E.; Tagliani, A.; Capoano, R.; D'amati, G.; Businaro, R.; Salvati, B.; Riganò, R. Plaqueinfiltrating T lymphocytes in patients with carotid atherosclerosis: an insight into the cellular mechanisms associated to plaque destabilization. J. Cardiovasc. Surg., 2012, PMID: 22669090.
25. Shoenfeld, Y.; Gerli, R.; Doria, A.; Matsuura, E.; Cerinic, M.M.; Ronda, N.; Jara, L.J.; Abu-Shakra, M.; Meroni, P.L.; Sherer, Y. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation, 2005, 112(21), 3337-3347. (Pubitemid 43739380)
26. Espinola-Klein, C.; Rupprecht, H.J.; Blankenberg, S.; Bickel, C.; Kopp, H.; Rippin, G.; Victor, A.; Hafner, G.; Schlumberger, W.; Meyer, J. AtheroGene Investigators. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation, 2002, 105(1), 15-21. (Pubitemid 34049136)
27. Murdaca, G.; Colombo, B.M.; Cagnati, P.; Gulli, R.; Spanò, F.; Puppo, F. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis, 2012, 224(2), 309-317.
28. Levy, A.P.; Moreno, P.R. Intraplaque hemorrhage. Curr. Mol. Med., 2006, 6, 479-488.
29. Virmani, R.; Kolodgie, F.D.; Burke, A.P.; Finn, A.V.; Gold, H.K.; Tulenko, T.N.; Wrenn, S.P.; Narula, J. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 2054-2061. (Pubitemid 41416300)
30. Kristiansen, M.; Graversen, J.H.; Jacobsen, C.; Sonne, O.; Hoffman, H.J.; Law, S.K.; Moestrup, S.K. Identification of the hemoglobin scavenger receptor. Nature, 2001, 409, 198-201.
31. Rother, R.P.; Bell, L.; Hillmen, P.; Gladwin, M.T. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA, 2005, 293, 1653-1662. (Pubitemid 40471796)
32. Tolosano, E.; Fagoonee, S.; Hirsch, E.; Berger, F.G.; Baumann, H.; Silengo, L.; Altruda, F. Enhanced splenomegaly and severe liver inflammation in haptoglobin/hemopexin double-null mice after acute hemolysis. Blood, 2002, 100, 4201-4208. (Pubitemid 35402055)
33. Giulivi, C.; Davies, K.J. Hydrogen peroxide-mediated ferrylhemoglobin generation in vitro and in red blood cells. Methods Enzymol., 1994, 231, 490-496.
34. Giulivi, C.; Cadenas, E. Heme protein radicals: formation, fate, and biological consequences. Free Radic. Biol. Med., 1998, 24(2), 269-279. (Pubitemid 28008805)
35. Silva, G.; Jeney, V.; Chora, A.; Larsen, R.; Balla, J.; Soares, M.P. Oxidized hemoglobin is an endogenous proinflammatory agonist that targets vascular endothelial cells. J. Biol. Chem., 2009, 284, 29582-29595.
36. Masuoka, N.; Sugiyama, H.; Ishibashi, N.; Wang, D.H.; Masuoka, T.; Kodama, H.; Nakano, T. Characterization of acatalasemic erythrocytes treated with low and high dose hydrogen peroxide. Hemolysis and aggregation. J. Biol. Chem., 2006, 281(31), 21728-21734. (Pubitemid 44181876)
37. Vallelian, F.; Pimenova, T.; Pereira, C.P.; Abraham, B.; Mikolajczyk, M.G.; Schoedon, G.; Zenobi, R.; Alayash, A.I.; Buehler, P.W.; Schaer, D.J. The reaction of hydrogen peroxide with hemo globin induces extensive alpha-globin crosslinking and impairs the interaction of hemoglobin with endogenous scavenger pathways. Free Radic. Biol. Med., 2008, 45(8), 1150-1158.
38. Ferreira, A.M.; Ferrari, M.I.; Trostchansky, A.; Batthyany, C.; Souza, J.M.; Alvarez, M.N.; López, G.V.; Baker, P.R.; Schopfer, F.J.; O'Donnell, V.; Freeman, B.A.; Rubbo, H. Macrophage activation induces formation of the anti-inflammatory lipid cholesterylnitrolinoleate. Biochem. J., 2009, 417(1), 223-234.
39. Buttari, B.; Profumo, E.; Petrone, L.; Pietraforte, D.; Siracusano, A.; Margutti, P.; Delunardo, F.; Ortona, E.; Minetti, M.; Salvati, B.; Riganò, R. Free hemoglobin: a dangerous signal for the immune system in patients with carotid atherosclerosis? Ann. N. Y. Acad. Sci., 2007, 1107, 42-50. (Pubitemid 47528780)
40. Buehler, P.W.; Abraham, B.; Vallelian, F.; Linnemayr, C.; Pereira, C.P.; Cipollo, J.F.; Jia, Y.; Mikolajczyk, M.; Boretti, F.S.; Schoedon, G.; Alayash, A.I.; Schaer, D.J. Haptoglobin preserves the CD163 hemoglobin scavenger pathway by shielding hemoglobin from peroxidative modification. Blood, 2009, 113(11), 2578-2586.
41. Michel, J.B.; Delbosc, S.; Ho-Tin-Noé, B.; Leseche, G.; Nicoletti, A.; Meilhac, O.; Martin-Ventura, J.L. From intraplaque haemorrhages to plaque vulnerability: biological consequences of intraplaque haemorrhages. Cardiovasc. Med. (Hagerstown), 2012, 13(10), 628-634.
42. Banerjee, S.; Jia, Y.; Siburt, C.J.; Abraham, B.; Wood, F.; Bonaventura, C.; Henkens, R.; Crumbliss, A.L.; Alayash, A.I. Haptoglobin alters oxygenation and oxidation of hemoglobin and decreases propagation of peroxide-induced oxidative reactions. Free Radic. Biol. Med., 2012, 53(6), 1317-1326.
43. Purushothaman, K.R.; Purushothaman, M.; Levy, A.P.; Lento, P.A.; Evrard, S.; Kovacic, J.C.; Briley-Saebo, K.C.; Tsimikas, S.; Witztum, J.L.; Krishnan, P.; Kini, A.; Fayad, Z.A.; Fuster, V.; Sharma, S.K.; Moreno, P.R. Increased expression of oxidationspecific epitopes and apoptosis are associated with haptoglobin genotype: possible implications for plaque progression in human atherosclerosis. J. Am. Coll. Cardiol., 2012, 60(2), 112-119.
44. Liu, X.; Spolarics, Z. Methemoglobin is a potent activator of endothelial cells by stimulating IL-6 and IL-8 production and E-selectin membrane expression. Am. J. Physiol. Cell. Physiol., 2003, 285, C1036-C1046. (Pubitemid 37296280)
45. Buttari, B.; Profumo, E.; Di Cristofano, C.; Pietraforte, D.; Lionetti, V.; Capoano, R.; Salvati, B.; Businaro, R.; Di Giammarco, G.; Riganò, R. Haemoglobin triggers chemotaxis of human monocytederived dendritic cells: possible role in atherosclerotic lesion instability. Atherosclerosis, 2011, 215(2), 316-322.
46. Galkina, E.; Ley, K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu. Rev. Immunol., 2009, 27, 165-197.
47. Kleinig, T.J.; Helps, S.C.; Ghabriel, M.N.; Manavis, J.; Leigh, C.; Blumbergs, P.C.; Vink, R. Hemoglobin crystals: a proinflammatory potential confounder of rat experimental intracerebral hemorrhage. Brain Res., 2009, 1287, 164-172.
48. Fenteany, G.; Glogauer, M. Cytoskeletal remodeling in leukocyte function. Curr. Opin. Hematol., 2004, 11, 15-24. (Pubitemid 38021717)
49. Buechler, C.; Ritter, M.; Orsó, E. Langmann, T.; Klucken, J.; Schmitz, G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J. Leukoc. Biol., 2000, 67, 97-103. (Pubitemid 30046823)
50. Bouhlel, M.A.; Derudas, B.; Rigamonti, E.; Dièvart, R.; Brozek, J.; Haulon, S.; Zawadzki, C.; Jude, B.; Torpier, G.; Marx, N.; Staels, B.; Chinetti-Gbaguidi, G. PPARgamma activation primes human monocytes into alternative M2 macrophages with antiinflammatory properties. Cell Metab., 2007, 6(2), 137-143. (Pubitemid 47189091)
51. (CpPLD) drives Th17 inflammation in human atherosclerosis. Proc. Natl. Acad. Sci. U S A., 2012, 109, 1222-7.
52. Gleissner, C.A. Macrophage Phenotype Modulation by CXCL4 in Atherosclerosis. Front. Physiol., 2012, 3, 1.
53. Niessner, A.; Weyand, C.M. Dendritic cells in atherosclerotic disease. Clin. Immunol., 2010, 134(1), 25-32.
54. Kaca, W.; Roth, R.I.; Levin, J. Hemoglobin, a newly recognized lipopolysaccharide (LPS)-binding protein that enhances LPS biological activity. J. Biol. Chem., 1994, 269, 25078-84. (Pubitemid 24311778)
55. Benagiano, M.; Munari, F.; Ciervo, A.; Amedei, A.; Paccani, S.R.; Mancini, F.; Ferrari, M.; Della Bella, C.; Ulivi, C.; D'Elios, S.; Baldari, C.T.; Prisco, D.; de Bernard, M.; D'Elios, M.M. Chlamydophila pneumoniae phospholipase D (CpPLD) drives Th17 inflammation in human atherosclerosis. Proc. Natl. Acad. Sci. U S A, 2012, 109(4), 1222-1227.
56. Calkins, C.E.; Esposito, M. Differences between normal and autoimmune T cell responses to autologous erythrocytes and haemoglobin: impairment of haptoglobin-mediated inhibition in NZB spleen cells. J. Autoimmun., 1996, 9, 453-462. (Pubitemid 26273635)
57. Noronha, P.A.; Vida, L.N., Park, C.L.; Honig, G.R. Hemoglobinspecific antibody in a multiply transfused patient with sickle cell disease. Blood, 1997, 89(6), 2155-2168.
58. Merbl, Y.; Zucker-Toledano, M.; Quintana, F.J.; Cohen, I.R. Newborn humans manifest autoantibodies to defined self molecules detected by antigen microarray informatics. J. Clin. Invest., 2007, 117(3), 712-718. (Pubitemid 46348529)
59. Hatnagar, H.; Kala, S.; Sharma, L.; Jain, S.; Kim, K.S.; Pal, R. Serum and organ-associated anti-hemoglobin humoral autoreactivity: association with anti-Sm responses and inflammation. Eur. J. Immunol., 2011, 41(2), 537-548.
60. Komita, H.; Zhao, X.; Taylor, J.L.; Sparvero, L.J.; Amoscato, A.A.; Alber, S.; Watkins, S.C.; Pardee, A.D.; Wesa, A.K.; Storkus, W.J. CD8+ T-cell responses against hemoglobin-beta prevent solid tumor growth. Cancer Res., 2008, 68(19), 8076-8084.
61. Rifkind, J.M.; Nagababu, E. Hemoglobin Redox Reactions and Red Blood Cell Aging. Antioxid. Redox Signal, 2012, Nov 9. [Epub ahead of print].
62. Michel, J.B.; Virmani, R.; Arbustini, E.; Pasterkamp, G. Intraplaque haemorrhages as the trigger of plaque vulnerability. Eur. Heart J., 2011, 32(16), 1977-1985, 1985a, 1985b, 1985c.
63. Maksimenko, A.V.; Vavaev, A.V. Antioxidant enzymes as potential targets in cardioprotection and treatment of cardiovascular diseases. Enzyme antioxidants: the next stage of pharmacological counterwork to the oxidative stress. Heart Int., 2012, 7(1), e3.
64. Levy, A.P.; Blum, S. Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E. Expert Rev. Cardiovasc. Ther., 2007, 5, 1105-1111. (Pubitemid 350303045)
65. Zhu, X.Y., Rodriguez-Porcel, M.; Bentley, M.D.; Chade, A.R.; Sica, V.; Napoli, C.; Caplice, N.; Ritman, E.L.; Lerman, A.; Lerman, L.O. Antioxidant intervention attenuates myocardial neovascularization in hypercholesterolemia. Circulation, 2004, 109, 2109-2115. (Pubitemid 38620220)
66. Hwang, P.K.; Greer, J. Interaction between hemoglobin subunits in the hemoglobin. Haptoglobin complex. J. Biol. Chem., 1980, 255, 3038-3041. (Pubitemid 10089257)
67. Boretti, F.S.; Buehler, P.W.; D'Agnillo, F.; Kluge, K.; Glaus, T.; Butt, O.I.; Jia, Y.; Goede, J.; Pereira, C.P.; Maggiorini, M.; Schoedon, G.; Alayash, A.I.; Schaer, D.J. Sequestration of extracellular hemoglobin within a haptoglobin complex decreases its hypertensive and oxidative effects in dogs and guinea pigs. J. Clin. Invest., 2009, 119, 2271-2280.
68. Arslan, F.; Smeets, M.B.; Buttari, B.; Profumo, E.; Riganò, R.; Akeroyd, L.; Kara, E; Timmers, L.; Sluijter, J.P.; van Middelaar, B.; den Ouden, K.; Pasterkamp, G.; Lim, S.K.; de Kleijn, D.P. Lack of haptoglobin results in unbalanced VEGFα/Angiopoietin-1 expression, intramural hemorrhage and impaired wound healing after myocardial infarction. J. Mol. Cell Cardiol., 2012, Dec 26. [Epub ahead of print].
69. Kalet-Litman, S.; Moreno, P.R.; Levy, A.P. The haptoglobin 2-2 genotype is associated with increased redox active hemoglobin derived iron in the atherosclerotic plaque. Atherosclerosis, 2010, 209, 28-31.
70. Etzerodt, A.; Moestrup, S.K. CD163 and inflammation: Biological, diagnostic and therapeutic aspects. Antioxid. Redox Signal., 2012, PMID: 22900885
71. Komori, H.; Watanabe, H.; Shuto, T.; Kodama, A.; Maeda, H.; Watanabe, K.; Kai, H.; Otagiri, M.; Maruyama, T. α1-Acid Glycoprotein Up-regulates CD163 via TLR4/CD14 Protein Pathway: possible protection against hemolysis-induced oxidative stress. J. Biol. Chem., 2012, 287(36), 30688-30700.
72. Baek, J.H.; D'Agnillo, F.; Vallelian, F.; Pereira, C.P.; Williams, M.C.; Jia, Y.; Schaer, D.J.; Buehler, P.W. Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy. J. Clin. Invest., 2012, 122, 1444-1458.
73. Kato, G.J. Haptoglobin halts hemoglobin's havoc. J. Clin. Invest., 2009, 119, 2140-2142.
74. Moreno, J.A.; Ortega-Gómez, A.; Delbosc, S.; Beaufort, N.; Sorbets, E.; Louedec, L.; Esposito-Farèse, M.; Tubach, F.; Nicoletti, A.; Steg, P.G.; Michel, J.B.; Feldman, L.; Meilhac, O. In vitro and in vivo evidence for the role of elastase shedding of CD163 in human atherothrombosis. Eur. Heart J., 2012, 33(2), 252-263.
75. Maher, B.M.; Dhonnchu, T.N.; Burke, J.P.; Soo, A.; Wood, A.E.; Watson, R.W. Statins alter neutrophil migration by modulating cellular Rho activity-a potential mechanism for statins-mediated pleotropic effects? J. Leukoc. Biol., 2009, 85(1), 186-193.
76. Samson, S.; Mundkur, L.; Kakkar, V.V. Immune response to lipoproteins in atherosclerosis. Cholesterol, 2012, 2012, 571846.
77. Mallat, Z.; Tedgui, A. Immunomodulation to combat atherosclerosis: the potential role of immune regulatory cells. Expert Opin. Biol. Ther., 2004, 4(9), 1387-1393. (Pubitemid 39222972)
78. Wigren, M.; Kolbus, D.; Dunér, P.; Ljungcrantz, I.; Söderberg, I.; Björkbacka, H.; Fredrikson, G.N.; Nilsson, J. Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine. J. Intern. Med., 2011, 269(5), 546-556.
79. Klingenberg, R.; Lebens, M.; Hermansson, A.; Fredrikson, G.N.; Strodthoff, D.; Rudling, M.; Ketelhuth, D.F.; Gerdes, N.; Holmgren, J.; Nilsson, J.; Hansson, G.K. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2010, 30(5), 946-952.
80. Klingenberg, R.; Ketelhuth, D.F.; Strodthoff, D.; Gregori, S.; Hansson, G.K. Subcutaneous immunization with heat shock protein-65 reduces atherosclerosis in Apoe(-/-) mice. Immunobiology, 2012, 217(5), 540-547.
81. van Puijvelde, G.H.; van Es, T.; van Wanrooij, E.J.; Habets, K.L.; de Vos, P.; van der Zee, R.; van Eden, W.; van Berkel, T.J.; Kuiper J. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2007, 27(12), 2677-2683. (Pubitemid 350158922)
82. Maron, R.; Sukhova, G.; Faria, A.M.; Hoffmann, E.; Mach, F.; Libby, P.; Weiner, H.L. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation, 2002, 106(13), 1708-1715.
83. Binder, C.J.; Shaw, P.X.; Chang, M.K.; Boullier, A.; Hartvigsen, K.; Hörkkö, S.; Miller, YI.; Woelkers, D.A.; Corr, M.; Witztum, J.L. The role of natural antibodies in atherogenesis. J. Lipid Res., 2005, 46(7), 1353-1363. (Pubitemid 43109798)
84. Arbustini, E.; Gambarin, F.I. Theranostic strategy against plaque angiogenesis. JACC Cardiovasc. Imaging., 2008, 1(5), 635-637.
85. Maiseyeu, A.; Badgeley, M.A.; Kampfrath, T.; Mihai, G.; Deiuliis, J.A.; Liu, C.; Sun, Q.; Parthasarathy, S.; Simon, D.I.; Croce, K.; Rajagopalan, S. In vivo targeting of inflammation-associated myeloid-related protein 8/14 via gadolinium immunonanoparticles. Arterioscler. Thromb. Vasc. Biol., 2012, 32(4), 962-970.